BURLINGTON, Mass.–(BUSINESS WIRE)–PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the promotion of Robert B. Geller, M.D. to General Manager. Dr. Geller joined the Company as Head of Medical earlier this year. In his new role as General Manager, Dr. Geller will bring his medical expertise to the team and continue to focus on serving more patients with myeloproliferative neoplasms (MPN).
“Since joining PharmaEssentia, Dr. Robert Geller has clearly demonstrated his strategic mindset and strong leadership,” said Dr. Ko-Chung Lin, PharmaEssentia Founder and CEO. “Robert has made important contributions to our BESREMi® (ropeginterferon alfa-2b-njft) medical strategy, including our focus on expanding the use of BESREMi as a frontline polycythemia vera treatment, consistent with the product label and the NCCN guidelines implemented earlier this year. More than 10,000 patients worldwide have already been treated with BESREMi, and we believe there is substantial opportunity for serving more patients.”
Prior to joining PharmaEssentia, Dr. Geller was most recently the Chief Medical Officer at Aravive and Senior Vice President of Medical Affairs at Coherus Biosciences. At Aravive, Dr. Geller oversaw the clinical trials supporting the development of batiraxcept, as well as safety, pharmacovigilance, and medical affairs. At Coherus, he led the Medical Affairs team to support UDENYCA® and the company’s oncology franchise and ophthalmology and immunology pipelines. Dr. Geller previously held medical roles at Heron Therapeutics, Alexion Pharmaceuticals, and Vion Pharmaceuticals.
Earlier in his career, he was on faculty at the University of Chicago and Emory University and served as Medical Director at several community and regional cancer centers, as well as a Partner in a large oncology/hematology practice. Dr. Geller received his M.D. from Harvard Medical School/Harvard-MIT Health Science Technology and a B.S./M.S. in physics from Massachusetts Institute of Technology.
About PharmaEssentia
PharmaEssentia (TPEx: 6446), headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversified pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.
For more information about PharmaEssentia USA, visit our website, LinkedIn or Twitter.
